Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Mutlu DEMİRAY"'
Autor:
Eylül Özgü, Benjamin G. Kaplan, Smruthy Sivakumar, Ethan S. Sokol, Esranur Aydın, Ünal Metin Tokat, Ashkan Adibi, Ebru Gül Karakoç, Jiancheng Hu, Razelle Kurzrock, Mutlu Demiray
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-11 (2024)
Abstract Background Kinase-impaired class III BRAF mutations have recently received attention as a possible prognostic factor and therapeutic target. Class III BRAF variants differ from class I and class II mutations in terms of mechanism of pathway
Externí odkaz:
https://doaj.org/article/e40e1f2264f54e588f65d74290b386b7
Autor:
Ünal Metin Tokat, Ashkan Adibi, Esranur Aydın, Eylül Özgü, Şevval Nur Bilgiç, Onur Tutar, Merve Özbek Doğançay, İrem Demiray, Mutlu Demiray
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 5838-5849 (2024)
There is currently no effective treatment strategy for recurrent/metastatic adenoid cystic carcinoma (R/M ACC). Furthermore, recent single-agent and combination immunotherapy trials have failed in unselected ACC cohorts, unlike non-ACC salivary gland
Externí odkaz:
https://doaj.org/article/7094e808ef284ab8b902545349bfdba9
Autor:
Ünal Metin Tokat, Şevval Nur Bilgiç, Esranur Aydın, Ashkan Adibi, Eylül Özgü, Onur Tutar, Mutlu Demiray
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Breast cancer (BC) is the leading cause of cancer-related mortality among women, and hormone receptor (HR)-positive subtype makes up the majority of all cases. The standard of care in HR + /HER2 − metastatic BC (MBC) is endocrine therapy (ET) plus
Externí odkaz:
https://doaj.org/article/df8be9a73e19472fa218aad7ac6273ef
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundMetastatic colon adenocarcinoma presents significant challenges in treatment, particularly when resistant to standard therapies. Precision oncology, guided by multidisciplinary tumor boards (MTBs), offers a promising way for individualized
Externí odkaz:
https://doaj.org/article/e043900dd69741819658ebc803f836f2
Autor:
Esranur Aydın, Ünal Metin Tokat, Eylül Özgü, Ashkan Adibi, Onur Tutar, Razelle Kurzrock, Mutlu Demiray
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
This paper presents a patient with a novel Ig-like-III domain fibroblast growth factor receptor (FGFR2) alteration (W290_P307>C) along with CDKN2A/B alterations and a cadherin 1 (CDH1) alteration. Initial responsiveness to pazopanib monotherapy was e
Externí odkaz:
https://doaj.org/article/c042fb9c5f2a4d9daefa88ee3383a68e
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Ewing’s sarcoma (ES) is a bone and soft tissue tumor that mainly occurs at a young age. The underlying cause of Ewing’s sarcoma is the formation of fusion proteins between FET family genes and ETS family genes. Tumors with FET/ETS fusion genes ca
Externí odkaz:
https://doaj.org/article/947eb492bb6c429a9e28526902e7c127
Autor:
Mutlu Demiray MD
Publikováno v:
Integrative Cancer Therapies, Vol 19 (2020)
Background: Tumor-specific DNA repair defects are ubiquitous in cancerous tissue, which offers a potential for clinical gain to build on these perturbations. Intravenous high-dose vitamin C (IVC) triggers the formation of hydrogen peroxide (H 2 O 2 )
Externí odkaz:
https://doaj.org/article/fce2a5538ca0452a968fbd420413c289
Autor:
Umut DİŞEL, Fatih KÖSE, Ahmet BİLİCİ, Mustafa ÖZGÜROĞLU, Sezer SAĞLAM, Mesut ŞEKER, Sercan AKSOY, İbrahim TEK, Nil Molinas MANDEL, Gökhan DEMİR, Çağatay ARSLAN, Mutlu DEMİRAY, Mehmet Akif ÖZTÜRK, Taflan SALEPÇİ, Yeşim ERALP, Fatih SELÇUKBİRİCİK, Gökçe TEMİZAŞ, Ebru Gül FİDAN
© 2022 by Turkish Society of Medical Oncology.Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap-plicability and functionality of the genomic alterations (GA). In this study, we e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac4d7eb3f22264639561fd4d8532643b
https://hdl.handle.net/20.500.12511/9715
https://hdl.handle.net/20.500.12511/9715
Autor:
Abdurrahim Kocyigit, Zahra Eskandari, Ebru Toksoy Oner, Fatemeh Bahadori, Mutlu Demiray, Mehmet S. Eroglu, Vildan Betul Yenigun
Chemoresistance (CR) is one of the reasons why chemotherapy agents like Gemcitabine (GMC) remain insufficient in healing breast cancer. Activation of Nuclear Factor-kappa B (NF-κB) during chemotherapy is known as an important factor in the developme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a7f6d2a252803d82a4d5e1b395cb511
http://hdl.handle.net/20.500.12645/29270
http://hdl.handle.net/20.500.12645/29270
Autor:
Mutlu Demiray, Fatemeh Bahadori
Publikováno v:
Proceedings, Vol 1, Iss 10, p 980 (2017)
Nuclear Factor-Kappa B (NF-kB) is a key inflammatory transcription factor expressed frequently in tumors which, has an important role in proliferation, apoptosis, inflammatory and immune response. Several recent preclinical and clinical studies have
Externí odkaz:
https://doaj.org/article/68b570d769a1431fb103a2f87e3ff834